The transaction is worth A$380 million
Bangalore-based Strides Arcolab has announced that it has completed acquisition of Aspen Pharmacare's generic pharmaceutical business and related assets in Australia.
The transaction is worth A$380 million(approx. $297 million).
"The transaction has now achieved closure on completion of closing conditions and statutory and regulatory approvals," Strides said in a statement.
"The acquired business will be integrated and consolidated with Strides effective September 1, 2015," the company added.
The business will operate under the Arrow Pharmaceuticals brand.